Technical Perspectives on Biotech Stocks -- Pain Therapeutics, Paratek Pharma, PDL BioPharma, and Progenics Pharma

Monday, April 16, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 16, 2018 /PRNewswire/ -- strives to bring the best free research to the investment community. 

Today we are offering reports on PTIE, PRTK, PDLI, and PGNX which can be accessed for free by signing up to Pre-market, scans Pain Therapeutics Inc. (NASDAQ: PTIE), Paratek Pharmaceuticals Inc.
(NASDAQ: PRTK), PDL BioPharma Inc. (NASDAQ: PDLI), and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX). According to TMRResearch's report titled, "Biotechnology Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017-2025," growing demand for new technologies, such as tissue engineering, fermentation, recombinant technology, and DNA sequencing, is expected to magnify the size of the Biotechnology industry. However, the growth of the global biotechnology market is likely to be hampered due to the high risks associated with genetically modified crops and organisms, and also due to ethical issues regarding clinical trials. All you have to do is sign up today for this free limited time offer by clicking the link below.

Pain Therapeutics

Austin, Texas-based Pain Therapeutics Inc.'s stock finished last Friday's session 3.53% higher at $8.51. A total volume of 116,459 shares was traded, which was above their three months average volume of 103,530 shares. The Company's shares have advanced 17.70% in the past month and 51.89% over the past year. The stock is trading above its 50-day and 200-day moving averages by 25.27% and 74.60%, respectively. Additionally, shares of Pain Therapeutics, which develops drugs for nervous system disorders in the US, have a Relative Strength Index (RSI) of 73.54.  

On March 19th, 2018, Pain Therapeutics announced that the US FDA will hold an Advisory Committee Meeting to discuss the New Drug Application for REMOXY ER (extended-release oxycodone CII). The tentative date for this meeting is June 26th, 2018. Details of the meeting agenda will be available in the Federal Register at a later date. Get the full research report on PTIE for free by clicking below at:

Paratek Pharmaceuticals

On Friday, shares in Boston, Massachusetts headquartered Paratek Pharmaceuticals Inc. ended the session 1.83% higher at $13.90. The stock recorded a trading volume of 374,748 shares. The Company's shares are trading 1.72% above their 50-day moving average. Moreover, shares of Paratek Pharma, which focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the US, have an RSI of 57.02.  

On April 04th, 2018, Paratek Pharma announced that the US FDA has accepted the New Drug Applications and granted a priority review for omadacycline, an investigational once-daily oral and intravenous broad-spectrum antibiotic. Paratek is seeking approval of omadacycline, a modernized tetracycline, for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Access the free research report on PRTK now by signing up at:

PDL BioPharma

Incline Village, Nevada headquartered PDL BioPharma Inc.'s shares declined 2.28%, closing the session at $3.00 with a total trading volume of 847,652 shares. The stock has gained 6.01% over the previous three months and 47.78% over the past year. The stock is trading 9.60% and 4.82% above their 50-day and 200-day moving averages, respectively. Additionally, shares of PDL BioPharma, which acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the US, Europe, and internationally, have an RSI of 56.23. Are you already registered with Wall St. Equities? Do so now for free, and get the report on PDLI at:

Progenics Pharmaceuticals

Last Friday at the close of trading, shares in New York City, New York-based Progenics Pharmaceuticals Inc. recorded a trading volume of 548,454 shares. The stock ended the session 0.27% lower at $7.32. The Company's shares have advanced 15.82% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 6.42% and 14.26%, respectively. Furthermore, shares of Progenics Pharma, which develops medicines and other technologies to target and treat cancer in the US and internationally, have an RSI of 51.82.  

On March 22nd, 2018, Progenics Pharma announced that it has received notification from the US FDA that the Agency will extend its review of the New Drug Application for AZEDRA® (iobenguane I 131) by three months to July 30th, 2018. The extension is the result of the submission of additional Chemistry, Manufacturing, and Controls information by the Company, which required additional time for FDA review. Aspiring Member, please take a moment to register below for your free research report on PGNX at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store